High Potency Active Pharmaceutical Ingredients (HPAPIs) pose one of the greatest respiratory risks in pharmaceutical manufacturing. Booming growth in the industry presents new and increasing safety and health challenges.

Deploying OSHA’s hierarchy of controls, once the use of engineering and administrative control options has been exhausted, respiratory protection equipment presents the last line of defense. With that, the use of PAPRs and SARs is increasing due to potential drug potency exposures during manufacturing and greater awareness of respiratory technology advances.

Download our whitepaper to learn more.